Latest Erythropoietin Stories
The CKD Market Will Decline Through 2017, Due to Genericization of Expensive Agents and Reimbursement Constraints in the U.S., According to Findings from Decision Resources Group BURLINGTON,
In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.
MarketResearchReports.Biz announces addition of new report “Chemotherapy Induced Anemia - Pipeline Review, H2 2013” to its database.
Medical Food Designed to Address the Increased Nutritional Requirements of Anemia Los Angeles, CA (PRWEB) September 04, 2013
In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS).
Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.
- An imitative word; an onomatopoetic word.